
via Phys.org
Researchers at the University of Notre Dame have discovered a way to make influenza visible to the naked eye, according to a new study in the Journal of the American Chemical Society.
By engineering dye molecules to target a specific enzyme of the virus, the team was able to develop a test kit that emitted fluorescent light when illuminated with a hand-held lamp or blue laser pointer.
Scientists used test samples that mimicked that of an infected patient, and spiked the samples with the enzyme, called neuraminidase, which had been purified from flu virus. The samples emit red fluorescent light as a positive indication of the influenza virus. Blue fluorescent light signals a negative result. The same process also allowed scientists to determine which of two approved antiviral drugs would be a better treatment option for the individual patient.
While still a prototype, researchers believe that with optimization the diagnostic could be developed to be used in point of care clinics or the home environment for a rapid, easy to interpret test for the presence of influenza.
“Viral cultures are the gold standard for diagnosis of influenza but take several days to develop. By targeting an enzyme inherent to the virus and identifying its presence in a sample, we can make a rapid determination of the influenza in a patient for an efficient and immediate diagnostic that would improve patient treatment and reduce overuse of antivirals,” said Bradley Smith, Emil T. Hofman Professor of Chemistry and Biochemistry in the Department of Chemistry and Biochemistry, director of the Notre Dame Integrated Imaging Facility and co-author of the study.
Smith and his team created a new method to detect neuraminidase, which is located on the surface of the virus. Researchers began by designing a dye molecule to emit red fluorescent light when it interacts with the neuraminidase. Following validation of enzyme recognition, researchers then tested the dye with two antiviral drugs used to treat influenza — Zanamivir, also known as Relenza, and Oseltamivir, known widely as Tamiflu. The antivirals are neuraminidase inhibitors. Samples containing dye and neuraminidase were combined with each of the antivirals and illuminated. Red fluorescence indicated the enzyme was still active, meaning the antiviral failed to inhibit the virus in that patient. Blue light indicated the enzyme had been blocked, presenting an effective treatment option.
The study, which received funding from the National Science Foundation and Notre Dame’s research initiative, Advanced Diagnostics and Therapeutics, focused specifically on fluorescence detection of the virus and efficacy of the two inhibitors. Smith’s team hopes to build upon these results in the future.
Learn more: Researchers shed new light on influenza detection
[osd_subscribe categories=’influenza’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “INFLUENZA’]
The Latest on: Influenza diagnostic
[google_news title=”” keyword=”Influenza diagnostic” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Duke spin-out scores $2M to forward diagnostics platform
A Duke spin-out has landed a federal grant to support the development of an at-home diagnostic test for multiple infectious diseases.
- Cost Associated With the Treatment of Influenza in a Managed Care Setting
The index date was defined as the date of the first occurrence of an influenza diagnosis during the study period. Medical claims were assessed from the index date to the end of the influenza ...
- How Accurate Are Rapid Influenza Diagnostic Tests?
A diagnosis of influenza can thus confidently be made in the presence of a positive RIDT. However, a negative RIDT result is unreliable and should be confirmed by traditional diagnostic tests if ...
- UT's 'lab-on-a-chip' tech now discerns between COVID-19 & flu
Researchers at the University of Texas at Austin have advanced their portable diagnostic device, the 'lab-on-a-chip', to differentiate between COVID-19 and the flu, paving the way for improved ...
- Abbott Offers up Rapid Influenza Diagnostic
Abbott Laboratories said its latest rapid influenza diagnostic test has been granted waived status under CLIA by FDA. The Abbott Park, IL-based company’s BiaxNow Influenza A&B Card 2 is for use with ...
via Google News and Bing News